ENTERA BIO LTD(NASDAQ:ENTX) stock News

ENTX Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Entera Bio

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

6 days ago - By: Benzinga - Mentions: LIXT SSKN GNPX DMAC ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

a month ago - By: Entera Bio Ltd.

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

a year ago - By: InvestorPlace

ENTX Stock Earnings: Entera Bio Meets EPS for Q2 2024

a year ago - By: BusinessInsider

ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024

2 months ago - By: The Motley Fool

Entera Bio Beats Q2 EPS Estimates

2 months ago - By: Entera Bio Ltd.

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

3 months ago - By: Entera Bio Ltd.

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

4 months ago - By: Yahoo Finance - Mentions: OPK GS

OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025

a year ago - By: InvestorPlace

ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024

4 months ago - By: Yahoo Finance - Mentions: OPK ATAI

Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT

5 months ago - By: Entera Bio Ltd.

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

7 months ago - By: Entera Bio Ltd.

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

7 months ago - By: Entera Bio Ltd.

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

8 months ago - By: Entera Bio Ltd.

Entera Bio to Participate in Upcoming Events

8 months ago - By: Entera Bio Ltd.

EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

9 months ago - By: Entera Bio Ltd.

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

a year ago - By: Entera Bio Ltd.

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

a year ago - By: Entera Bio Ltd.; OPKO Health, Inc.

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

a year ago - By: Entera Bio Ltd.

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

a year ago - By: Entera Bio Ltd.

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

a year ago - By: InvestorPlace - Mentions: BITF CRON

3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years

a year ago - By: InvestorPlace - Mentions: BITF ACHR UAL STLA

3 Meme Stocks That Can Surge by 200% Before 2025

a year ago - By: InvestorPlace - Mentions: ACTE ATNM

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns

a year ago - By: InvestorPlace - Mentions: RIOT ACB NVAX GME

3 Meme Stocks to Buy on the Dip: June 2024

a year ago - By: InvestorPlace - Mentions: BITF ACHR REI BLNK ...

7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months

a year ago - By: InvestorPlace - Mentions: JOBY SLDP F

Rag to Riches: 3 Penny Stocks That Could Make Early Investors Rich

a year ago - By: InvestorPlace - Mentions: CRON BLDE

3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024

a year ago - By: InvestorPlace - Mentions: ACET ATNM

Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024

a year ago - By: InvestorPlace - Mentions: ATNM ATOS NVAX PLUG ...

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar

a year ago - By: InvestorPlace - Mentions: NVAX SNY ACST KPTI

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom

a year ago - By: Entera Bio Ltd.

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

a year ago - By: Entera Bio Ltd.

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

2 years ago - By: InvestorPlace - Mentions: ALPN RZLT

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

2 years ago - By: Entera Bio Ltd.

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

2 years ago - By: Entera Bio Ltd.

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

2 years ago - By: Entera Bio Ltd.

ENTERA BIO LTD (ENTX) Stock News

ENTX Latest News, Press Relases and Analysis

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

ENTX Stock Earnings: Entera Bio Meets EPS for Q2 2024

ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024

Entera Bio Beats Q2 EPS Estimates

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025

ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024

Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Events

EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years

3 Meme Stocks That Can Surge by 200% Before 2025

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns

3 Meme Stocks to Buy on the Dip: June 2024

7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months

Rag to Riches: 3 Penny Stocks That Could Make Early Investors Rich

3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024

Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates